Kloke O - Search Results

1

Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.

Niederle N, Kloke O, May D, Becher R, Osieka R, Schmidt CG. Niederle N, et al. Among authors: kloke o. Invest New Drugs. 1987;5 Suppl:S19-25. doi: 10.1007/BF00207259. Invest New Drugs. 1987. PMID: 3474219

2

Interferon alfa-2b in the treatment of chronic myelogenous leukemia.

Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG. Niederle N, et al. Among authors: kloke o. Semin Oncol. 1987 Jun;14(2 Suppl 2):29-35. Semin Oncol. 1987. PMID: 3473689

3

[alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].

Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG. Niederle N, et al. Among authors: kloke o. Dtsch Med Wochenschr. 1986 May 16;111(20):767-72. doi: 10.1055/s-2008-1068529. Dtsch Med Wochenschr. 1986. PMID: 3516621 Clinical Trial. German.

4

Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients.

Niederle N, Moritz T, Kloke O, Wandl U, May D, Becher R, Franz T, Opalka B, Schmidt CG. Niederle N, et al. Among authors: kloke o. Eur J Cancer. 1991;27 Suppl 4:S7-14. doi: 10.1016/0277-5379(91)90556-s. Eur J Cancer. 1991. PMID: 1799485

5

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.

Wandl UB, Kloke O, Nagel-Hiemke M, Moritz T, Becher R, Opalka B, Holtkamp W, Bartels H, Seeber S, Niederle N. Wandl UB, et al. Among authors: kloke o. Br J Haematol. 1992 Aug;81(4):516-9. doi: 10.1111/j.1365-2141.1992.tb02984.x. Br J Haematol. 1992. PMID: 1390238

6

Treatment of chronic myelogenous leukemia with different cytokines.

Wandl UB, Opalka B, Kloke O, Nagel-Hiemke M, Moritz T, Niederle N. Wandl UB, et al. Among authors: kloke o. Semin Oncol. 1992 Apr;19(2 Suppl 4):88-94. Semin Oncol. 1992. PMID: 1553580 Clinical Trial.

7

Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Opalka B, et al. Among authors: kloke o. Blood. 1991 Nov 1;78(9):2188-93. Blood. 1991. PMID: 1932740 Free article. Clinical Trial.

8

Treatment of chronic myelogenous leukemia with interferons alpha and gamma.

Kloke O, May D, Wandl U, Becher R, Opalka B, Beer U, Niederle N. Kloke O, et al. Blut. 1990 Jul;61(1):45-6. doi: 10.1007/BF01739433. Blut. 1990. PMID: 2117476

9

DNA-flow cytometry studies in blood and marrow cells from chronic myelogenous leukemia patients treated with interferon alpha-2b.

Wandl UB, May D, Peltzer T, Kloke O, Opalka B, Niederle N, Streffer C. Wandl UB, et al. Among authors: kloke o. Leuk Res. 1990;14(10):905-8. doi: 10.1016/0145-2126(90)90180-h. Leuk Res. 1990. PMID: 2259227

10

[Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon].

Doberauer C, Niederle N, Kloke O, Kurschel E, Schmidt CG. Doberauer C, et al. Among authors: kloke o. Onkologie. 1987 Dec;10(6):340-4. doi: 10.1159/000216440. Onkologie. 1987. PMID: 2450326 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters